Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

US · MD National Institutes of Health (NIH) grant open #PAR-25-183

Response due Oct 15, 2027 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting R33 grant applications for early-stage clinical trials testing pharmacologic or neuromodulatory device-based interventions for the treatment of mental disorders. This is a federal grant opportunity (PAR-25-183) requiring a clinical trial component. The opportunity is open from November 2024 through October 2027, providing a multi-year window for applicants to submit proposals focused on advancing mental health treatment research.

What they want

Technical requirements

Clinical trial required
Research must target pharmacologic or neuromodulatory device-based interventions
Interventions must be directed at treatment of mental disorders
R33 grant mechanism applies (early-stage exploratory/developmental research)

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

No dollar value or award ceiling disclosed — budget scope is unclear for prospective applicants
Rolling/multi-year close date (Oct 2027) with unspecified individual submission deadlines — actual due dates likely governed by NIH's standard receipt date schedule not included in this notice

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Early Stage Testing of Pharmacologic or Ne…

Due Oct 15

Onboard ↗